Rtw Investments, LP Avadel Pharmaceuticals PLC Transaction History

Rtw Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $23.2 Million - $31.9 Million	1,850,640 Added 26.64%	8,798,558 $149 Million
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $1.82 Million - $2.75 Million	-188,497 Reduced 2.64%	6,947,918 $98.1 Million
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $3.36 Million - $5.21 Million	325,774 Added 4.78%	7,136,415 $73.5 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $9.06 Million - $17.6 Million	1,068,702 Added 18.61%	6,810,641 $112 Million
Q1 2021 May 14, 2021	BUY	$6.61 - $10.07 $2.34 Million - $3.57 Million	354,426 Added 6.58%	5,741,939 $51.9 Million
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $104,664 - $165,423	20,808 Added 0.39%	5,387,513 $36 Million
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $301,877 - $540,012	60,135 Added 1.13%	5,366,705 $27 Million
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $5 Million - $8.11 Million	690,000 Added 14.95%	5,306,570 $42.9 Million
Q1 2020 May 15, 2020	BUY	$4.06 - $10.64 $4.93 Million - $12.9 Million	1,215,136 Added 35.72%	4,616,570 $36.7 Million
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $11.4 Million - $26.2 Million	3,401,434 New	3,401,434 $25.7 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Rtw Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Rtw Investments, LP with notifications on news.